A Novel TBI Free Conditioning Protocol for Haploidentical Transplant in Acquired Aplastic Anemia: (FluCAB-Prime)
A Novel TBI Free Conditioning Protocol for Haploidentical Hematopoeitic Stem Cell Transplant in Acquired Aplastic Anemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Xanab akram
- Phone Number: 03325346564
- Email: xanab.akram@gmail.com
Study Locations
-
-
Punjab
-
Rawalpindi, Punjab, Pakistan, 46000
- Recruiting
- NIBMT
-
Contact:
- Tariq Mehmood Satti, FCPS, MCPS
- Phone Number: 201 +92-51-9270076
- Email: tariqmahmood_satti@yahoo.com
-
Contact:
- FCPS,FACP
-
Sub-Investigator:
- Xanab Akram
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age >2 years and < 60 years
- Karnofsky performance status >= 70%
Aplastic Anemia that meets the following criteria:
i. Peripheral Blood (must fulfill 2 of 3): ii. <500 neutrophils iii. <20,000 platelets iv. absolute reticulocyte count <40,000/microL
- Bone Marrow (must be ): markedly hypocellular (<25% of normal cellularity) with absence of reticulin and abnormal infiltrate
Exclusion Criteria:
- Presence of donor specific antibodies
- Fanconi anemia
- Cytogenetic abnormalities suggestive of myelodysplastic syndrome
- Prior HSCT
- Human immunodeficiency virus infection
- Active Hepatitis B virus infection
- Active /uncontrolled bacterial, viral , fungal infection or Tuberculosis
- Psychiatric illness
- Poor cardiac function (ejection fraction <40%)
- Poor pulmonary function (Forced vital capacity <50% predicted)
- Poor liver function (bilirubin >= 2mg/dL)
- Poor renal function (creatinine >= 2.0mg/dL or creatinine clearance <40)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TBI free Haploidentical HSCT
Recipients will receive a reduced intensity conditioning regimen of ''Fludarabine'' 30 mg/m2 IV daily from day -7 to -3, ''Cyclophosphamide'' 14.5-30 mg/kg IV daily on day -6 and -5 , ''rabbit Antithymocyte globulin'' 5 mg /kg/day from day -6 to day-3; ''Busulphan'' IV 3.2 mg per kg/day in 02 divided doses on day -3 and day-2, ''Granulocyte Colony Stimulating factor primed Bone marrow harvest'' and/OR ''PBSC'' graft on day 0 and day +1 respectively and Graft versus host disease prophylaxis with ''post-transplant cyclophosphamide'' administered at a dose of 50mg/kg/day given daily on days +3 and +5 post-transplant and ''cyclosporine'' from day +5, ''mycophenolate mofetil'' from day+5 to day+35.
|
''Busulphan'' will be used in place of ''TBI'' in equivalent myelotoxic dose to facilitate engraftment , ''ATG'' will be used to reduce GVHD and facilitate engraftment while ''combine PBSC'' and/OR ''Bone marrow harvest'' will be used
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with overall survival
Time Frame: from the date of transplant to 1 year post transplant
|
overall survival is defined as the time interval from date of transplant to death or to last follow-up, whichever occurs first.
|
from the date of transplant to 1 year post transplant
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants with Disease free survival
Time Frame: from the date of transplant to 1 year post transplant
|
from time of transplant to death or last follow up
|
from the date of transplant to 1 year post transplant
|
|
Time of Neutrophil engraftment
Time Frame: from the date of transplant to 10 to day 28 post transplant
|
first of 3 consecutive days with Absolute neutrophil count> 0.5
|
from the date of transplant to 10 to day 28 post transplant
|
|
Frequency of Graft versus host disease
Time Frame: from the date of transplant to acute upto 100 day post transplant, chronic >100 days post transplant
|
as per clinical and histopathological diagnosis
|
from the date of transplant to acute upto 100 day post transplant, chronic >100 days post transplant
|
|
Rate of Complications
Time Frame: from the date of transplant to 1 year from day of transplantation
|
both infectious and non infectious
|
from the date of transplant to 1 year from day of transplantation
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Tariq Mehmood Satti, FCPS, NIBMT
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Bone Marrow Diseases
- Hematologic Diseases
- Bone Marrow Failure Disorders
- Anemia
- Anemia, Aplastic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Cyclophosphamide
Other Study ID Numbers
Other Study ID Numbers
- AFBMTC-HAPLO-AA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.